File Photo/NBD

1. Eli Lilly's Weight Loss Drug Approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound (tirzepatide) injection for the treatment of adult obesity and overweight. In a statement, Lilly said it expects Zepbound to be available in the U.S. market by the end of the year, with a price of $1,059.87 per month.

2. General Motors' Cruise Recalls 950 Self-Driving Cars Due to Safety Concerns

General Motors' self-driving car subsidiary Cruise has announced that it will recall 950 self-driving cars nationwide due to a previous traffic accident. The Cruise's self-driving system (ADS) software's collision detection subsystem may not respond appropriately after an accident.

3. ChatGPT Service Experiences Major Outage

On the evening of November 9, 2023, at around 10:00 p.m., a large number of users reported that OpenAI's ChatGPT and API were not working. The outage lasted approximately 100 minutes, and OpenAI has classified the event as a "major outage." CEO Sam Altman said that the new features released this week have seen far more usage than expected and that due to the load, the service may be unstable in the short term.

4. Google's Generative AI Feature Available in 120 Countries and Regions

Google announced that its search engine's generative AI service, Search Generation Experience (SGE), will be expanded to 120 countries and regions, and will add support for four new languages and multiple new features.

5. General Motors and Stellantis Enter the Field of Rare-Earth-Free Motors

General Motors and Stellantis have partnered with U.S. startup Niron Magnetics to develop the next generation of rare-earth-free permanent magnet motors. Niron Magnetics claims to have a patented method for manufacturing high-performance magnets using only iron and nitrogen, eliminating the need for rare earth elements.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using.

Editor: Alexander